ImmunoCellular Therapeutics (IMUC) Hitting New Highs Researching Stem Cells

Global Hunter Securities got it right when the analysts set a “buy” rating and a $5.00 price target on Penny Stock ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC.OB) back on December 1, 2012. IMUC announced the allowance of U.S. patent claims related to the Company’s method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells (CSC).

IMUC closing price yesterday was $1.64, up 5.81% (+0.09).
IMUC traded volume of 553,369.
IMUC is trading:

  • $0.39 above its 20 day moving average,
  • $0.34 above its 10 day moving average and
  • $0.23 above its 5 day moving average.


ImmunoCellular Therapeutics is a biotechnology company focused on the development of novel immune-based cancer therapies> ImmunoCellular received notice from the U.S. Patent and Trademark Office that a patent titled “Cancer Stem Cell Antigen Vaccines and Methods,” which covers various methods of using dendritic cells combined with antigens derived from glioblastoma CSCs for the treatment of GBM has been allowed.

“The notice of allowance for this patent provides support for our strong intellectual property protection that we are building in the treatment of cancer by targeting cancer stem cells,” said John Yu, MD, ImmunoCellular’s Chairman of the Board and Chief Scientific Officer and a co-inventor of the technology covered by the patent that has been exclusively licensed to the Company. “We continue to actively develop our CSC platform as we believe it has significant potential in the treatment of cancer.”

ImmunoCellular Therapeutics is currently conducting a Phase-II double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. A separate patent covering a method of treating neural cancers using ICT-107 was recently issued by the U.S. Patent and Trademark Office on January 17, 2012.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens including those associated with cancer stem cells for glioblastoma treatment.

To learn more about IMUC, please visit www.imuc.com.

IMUC.OB is a “MUST ADD” to watch lists as this could be the beginning of “good news” to begin rolling out from the company as it continues its Phase II clinical trials.

Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett

If you really want to make some considerable profits from the stock market, it is possible to make a considerable amount of money on penny stock trading. When you find the right penny stock to buy, knowing when to buy and sell is the second most important tool to maximizing your profits.

Being technical, analytical or just flat-out greedy when trading penny stocks is the easiest way to limit profits and, sometimes, even lose your entire investment. You need to have a strong and strict strategy to achieve your goal of maximizing profits while minimizing risks in penny stocks.

Listed below are a few of the many points each and every penny stock investor needs to discover.

  • Do your own research.
  • Trade Responsibly.
  • Verify everything.
  • Move Fast or Get Left Behind.
  • Do not use market orders to enter a position, use limit orders.
  • Have a System That fits You.
  • If a Stock Gaps Open, Look for Pullbacks to Enter.
  • Plan a Trade and Trade a Plan.
  • Always use stop loss orders to protect yourself.
  • Positive Self- Belief.
  • Keep trading as Part of a Balanced life.
  • If a stock breaks below our alert price GET OUT. Do not wait.
  • View Trading as a Score in Points and Not In Money:
  • Always take your profits whenever you can. Do Not Be Greedy.
  • Work Hard at Learning How to Trade Properly and Keep Working.
  • Do something to make someone else’s life better today.

About AimHighProfits.com

AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential.

Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.

We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.

Aim High Profits Disclaimer

This is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision.

Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

For a complete explanation, please visit our disclaimer page.

Last updated by at .

0
  Recent Penny Stock News